English  |  正體中文  |  简体中文  |  Items with full text/Total items : 16812/19099 (88%)
Visitors : 6917523      Online Users : 250
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.cnu.edu.tw/handle/310902800/31598


    標題: Recombinant adeno-associated virus vector carrying the thrombomodulin lectin-like domain for the treatment of abdominal aortic aneurysm
    作者: Lai, Chao-Han
    Wang, Kuan-Chieh
    Kuo, Cheng-Hsiang
    Lee, Fang-Tzu
    Cheng, Tsung-Lin
    Chang, Bi-Ing
    Yang, Yu-Jen
    Shi, Guey-Yueh
    Wu, Hua-Lin
    貢獻者: Natl Cheng Kung Univ,Natl Cheng Kung Univ Hosp, Dept Surg, Coll Med
    Natl Cheng Kung Univ, Coll Med, Cardiovasc Res Ctr
    Natl Cheng Kung Univ, Dept Biochem & Mol Biol, Coll Med
    Chia Nan Univ Pharm & Sci, Dept Tourism Management, Coll Recreat & Hlth Management
    Kaohsiung Med Univ, Dept Physiol, Coll Med
    Kaohsiung Med Univ, Coll Med, Orthopaed Res Ctr
    關鍵字: Adeno-associated virus
    Thrombomodulin
    Abdominal aortic aneurysm
    Receptor for advanced glycation end
    product
    High-mobility group box 1
    Inflammation
    日期: 2017-07
    上傳時間: 2018-11-30 15:49:41 (UTC+8)
    出版者: Elsevier Ireland Ltd
    摘要: Background and aims: Thrombomodulin (TM), through its lectin-like domain (TMD1), sequesters proinflammatory high-mobility group box 1 (HMGB1) to prevent it from engaging the receptor for advanced glycation end product (RAGE) that sustains inflammation and tissue damage. Our previous study demonstrated that short-term treatment with recombinant TM containing all the extracellular domains (i.e., rTMD123) inhibits HMGB1-RAGE signaling and confers protection against CaCl2-induced AAA formation. In this study, we attempted to further optimize TM domains, as a potential therapeutic agent for AAA, using the recombinant adeno-associated virus (AAV) vector. Methods: The therapeutic effects of recombinant TMD1 (rTMD1) and recombinant AAV vectors carrying the lectin-like domain of TM (rAAV-TMD1) were evaluated in the CaCl2-induced AAA model and angiotensin II-infused AAA model, respectively. Results: In the CaCl2-induced model, treatment with rTMD1 suppressed the tissue levels of HMGB1 and RAGE, macrophage accumulation, elastin destruction and AAA formation, and the effects were comparable to a mole-equivalent dosage of rTMD123. In the angiotensin II-infused model, a single intravenous injection of rAAV-TMD1 (1011 genome copies), which resulted in a persistently high serum level of TMD1 for at least 12 weeks, effectively attenuated AAA formation with suppression of HMGB1 and RAGE levels and inhibition of proinflammatory cytokine production, macrophage accumulation, matrix metalloproteinase activities and oxidative stress in the aortic wall. Conclusions: These findings corroborate the therapeutic potential of the TM lectin-like domain in AAA. The attenuation of angiotensin II-infused AAA by one-time delivery of rAAV-TMD1 provides a proof-ofconcept validation of its application as potential gene therapy for aneurysm development. (C) 2017 Elsevier B.V. All rights reserved.
    關聯: Atherosclerosis, v.262, pp.62-70
    Appears in Collections:[觀光事業管理系(含溫泉所)] 期刊論文

    Files in This Item:

    File Description SizeFormat
    index.html0KbHTML49View/Open


    All items in CNU IR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback